SCHEMBL21723639

SCHEMBL21723639

COc1ccc(-c2cc3c(s2)c(-c2ccccc2)cc(=O)n3C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.47
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 5/20 0.46
KDM4E B2RXH2 5/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 4/20 0.45
HPGD P15428 4/20 0.45
MAPT P10636 3/20 0.45
TP53 P04637 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
MAPK1 P28482 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
GABRA1 P14867 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21723987 0.95 NPC1 (0.48) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL21723934 0.86 NPC1 (0.42) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL21723952 0.84 GSK3B (0.41) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL21723989 0.82 NPC1 (0.48) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL21723978 0.80 HSD17B10 (0.44) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL25259095 0.79 KDM4E (0.37) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL23452001 0.78 LMNA (0.43) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL23451957 0.77 GABRG2 (0.46) HSD17B10RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL25297318 0.76 NPC1 (0.40) RAB9ASMN1; SMN2NPC1KDM4EMEN1
SCHEMBL23452066 0.74 ALDH1A1 (0.53) HSD17B10RAB9ASMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415813-B2 Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) 2025-09-16 US disclosed
US-11306103-B2 Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY 2022-04-19 US disclosed
US-11306103-B2 Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY 2022-04-19 US disclosed
US-20210332063-A1 METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KP) 2021-10-28 US disclosed
US-20210332063-A1 METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KP) 2021-10-28 US disclosed
US-20210171539-A1 NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) 2021-06-10 US disclosed
US-20210171539-A1 NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) 2021-06-10 US disclosed
WO-2020036243-A1 METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR 한국해양과학기술원 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210332063-A1 METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR FARS2, CYP4F11, CYP4B1 HSD17B10 2367/4885RAB9A 3000/4885SMN1; SMN2 4636/4885
US-12415813-B2 Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor FARS2, CYP4F11, CYP4B1 HSD17B10 2367/4885RAB9A 3000/4885SMN1; SMN2 4636/4885
US-20210171539-A1 NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF BRD4, BRPF3, AFF4 HSD17B10 1772/4885RAB9A 4070/4885SMN1; SMN2 4333/4885
US-11306103-B2 Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof BRD4, BRPF3, AFF4 HSD17B10 1574/4885RAB9A 4124/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.